Early relapse after single auto-SCT for multiple myeloma is a major predictor of survival in the era of novel agents

Getting to the root of the problem: the causes of relapse in multiple myeloma

(2014) Kim C Chan Chung et al.   Expert Review of Anticancer Therapy

Trends in Utilization and Outcomes of Autologous Transplantation as Early Therapy for Multiple Myeloma

(2013) Luciano J. Costa et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Xbp1s-Negative Tumor B Cells and Pre-Plasmablasts Mediate Therapeutic Proteasome Inhibitor Resistance in Multiple Myeloma

(2013) Chungyee Leung-Hagesteijn et al.   CANCER CELL

Long-Term Analysis of the IFM 99 Trials for Myeloma: Cytogenetic Abnormalities [t(4;14), del(17p), 1q gains] Play a Major Role in Defining Long-Term Survival

(2012) Hervé Avet-Loiseau et al.   JOURNAL OF CLINICAL ONCOLOGY

High-risk cytogenetics and persistent minimal residual disease by multiparameter flow cytometry predict unsustained complete response after autologous stem cell transplantation in multiple myeloma

(2011) B. Paiva et al.   BLOOD

Rapid early monoclonal protein reduction after therapy with bortezomib or bortezomib and pegylated liposomal doxorubicin in relapsed/refractory myeloma is associated with a longer time to progression

(2011) Jatin Shah et al.   CANCER

Treatment of Newly Diagnosed Multiple Myeloma in Transplant-Eligible Patients

(2011) Shaji Kumar   Current Hematologic Malignancy Reports

Bortezomib resistance in mantle cell lymphoma is associated with plasmacytic differentiation

(2010) P. Perez-Galan et al.   BLOOD

Novel agents improve survival of transplant patients with multiple myeloma including those with high-risk disease defined by early relapse (

(2010) Christopher P. Venner et al.   LEUKEMIA & LYMPHOMA

Complete remission in multiple myeloma examined as time-dependent variable in terms of both onset and duration in Total Therapy protocols

(2009) A. Hoering et al.   BLOOD

Integrating Novel Therapies in the Transplant Paradigm

(2009) Jean-Luc Harousseau   CANCER JOURNAL

The Role of High-Dose Therapy With Autologous Stem Cell Support in the Era of Novel Agents

(2009) Michel Attal et al.   SEMINARS IN HEMATOLOGY

Impact of early relapse after auto-SCT for multiple myeloma

(2008) S Kumar et al.   BONE MARROW TRANSPLANTATION

Advances in therapy of multiple myeloma

(2008) Joan Bladé et al.   CURRENT OPINION IN ONCOLOGY